Most Recent Articles about ONCE
WeWork chairman once called John Legere a 'con artist' — now they could run WeWork together https://www.cnbc.com/2019/11/11/weworks-marcelo-claure-once-called-john-legere-con-artist-in-tweet.html Nov 11, 2019 - With reports that T-Mobile CEO John Legere could be the next head of WeWork, it's worth recounting his testy relationship with Marcelo Claure, WeWork's chairman.
Once a source of panic, the yield curve is validating stocks' comeback and may crown the winners https://www.cnbc.com/2019/11/11/once-a-source-of-panic-yield-curve-is-validating-stocks-comeback.html Nov 11, 2019 - It's no coincidence that investors are getting more positive on the stock market as the yield curve has been steepening.
Criteo: Once Again, No Rush To Buy The Dip https://seekingalpha.com/article/4305309-criteo-rush-buy-dip?source=feed_all_articles Nov 11, 2019 - The competitive landscape has continued to deteriorate for the company during the last year.It appears increasingly unlikely that a $1 billion business can withstand overt hostility from the likes of

Related Companies

Name Exchange Price Mkt Cap
MNTA Momenta Pharmaceuticals, Inc. NASDAQ $27.4 $2.15B
RGNX REGENXBIO Inc. NASDAQ $70.3974 $2.27B
XLRN Acceleron Pharma Inc. NASDAQ $52 $2.39B
CRSP CRISPR Therapeutics AG NASDAQ $50.31 $2.39B
HALO Halozyme Therapeutics, Inc. NASDAQ $16.68 $2.41B
Sector: Health Care > Industry: Biotechnology: Biological Products (No Diagnostic Substances)